Trinity Delta Lighthouse: Nexstim
Trinity Delta view: TMS (Transcranial Magnetic Stimulation) offers clear clinical and economic benefits in treating MDD (major depressive disorder). However, such treatment is limited by its long duration, typically five outpatient sessions per week over six weeks. Accelerated treatment regimens employing shorter, more intensive protocols have clear potential, with numerous additional benefits to patients, providers, and payors. Such protocols require highly accurate targeting, hence Nexstim’s NBT (Navigated Brain Therapy) system is particularly well suited as the SmartFocus platform provides precise, reliable, and reproducible navigation. Further development of accelerated protocols are a key component of Nexstim’s 2020-24 strategic plan, with successful outcomes in the future registrational studies opening a material, and commercially attractive, new inpatient treatment segment for NBT.Nexstim Oyj. Nexstim Oyj is a Finland-based medical technology company. It is focused on improving rehabilitation for stroke patients through the use of noninvasive brain stimulation. Its offering comprises: a diagnostic tool for brain surgery planning, Navigated Brain Stimulation (NBS) System, which comprises navigated transcranial magnetic stimulation (nTMS) device for presurgical mapping (PSM) of the motor and speech cortices; and a device for stroke therapy called Navigated Brain Therapy (NBT) System, which focuses stimulation on targeted locations in the brain in order to enhance rehabilitation process. The NBT System targets upper limb motor disability and is under Phase III pivotal clinical trial study at rehabilitation sites in the United States. The Company's systems are used in over 100 facilities in research, therapy and neurosurgical planning purposes. Nexstim Oyj has two subsidiaries: Nexstim Inc and Nexstim Germany GmbH.
We are experienced healthcare and life sciences analysts providing the highest quality service to companies in these sectors and to investors. We have expertise in the fields of the biotech, medtech , specialty pharma and consumer health sectors.
The old-fashioned values of the City enabled London to become a global financial centre, and we pride ourselves for our integrity and professionalism, where our word is our bond. This applies to our research, and all interactions with companies, the buyside and other partners.
We also firmly believe that by putting our clients first, we create long term value for all stakeholders.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.